# A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Source: https://onco.cc/trials/nct07288203/  
OnCo record `nct07288203` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lifileucel in melanoma and skin cancer, run by Iovance Biotherapeutics, Inc., active and no longer recruiting.

## Summary

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is a phase 2 interventional study registered as NCT07288203 by Iovance Biotherapeutics, Inc., with 100 participants planned, started 2025-11-28 and due to reach its primary completion in 2032-12. Interventions recorded: Lifileucel. Conditions listed: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07288203
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07288203: https://clinicaltrials.gov/study/NCT07288203

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- drugs: [Lifileucel](https://onco.cc/drugs/lifileucel/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct07288203.json